How Neura Is Bringing Precision Genomics to Brain Health Supplementation

The Supplement Aisle Is Lying to You

Walk into any pharmacy, health food store, or big-box retailer and you'll find the same thing: walls of nearly identical brain health supplements making nearly identical claims. "Supports memory." "Promotes focus." "Enhances mental clarity." The bottles change. The claims don't. And behind the marketing, almost none of it accounts for the single most important variable in whether a supplement actually works for you — your biology.

This isn't a minor oversight. It's a foundational flaw in how the $50 billion global supplement industry operates. The field of nutrigenomics — the study of how genetic variants influence nutrient metabolism — has spent two decades demonstrating that individual genetic differences dramatically alter everything from how your body converts folic acid to usable methylfolate, to how quickly your brain breaks down dopamine, to how aggressively your neurons respond to inflammatory signals. What supports peak cognitive function in one person can be inert — or actively counterproductive — in another.

Science knew this. The supplement industry ignored it. Neura is here to close that gap.

What Neura Does

Neura is a precision brain health platform built on a simple but powerful premise: your brain supplement should be derived from your genome, not from a marketing brief.

The process starts with a painless saliva test mailed directly to your door. Neura's panel analyzes over 80 genetic variants with direct relevance to cognitive function, including:

• COMT and MAO variants — governing how quickly your prefrontal cortex clears dopamine, with profound implications for focus, stress response, and executive function
• MTHFR polymorphisms — determining whether you can effectively utilize standard folic acid or require the bioactive methylfolate form, critical for neurotransmitter synthesis and homocysteine regulation
• APOE status — the most well-studied genetic risk factor for neuroinflammation and long-term cognitive decline
• BDNF variants — influencing neuroplasticity, how readily your brain forms new synaptic connections, and how you respond to cognitive training

From this genomic profile, Neura formulates a supplement stack manufactured in an FDA-registered facility. The distinction here is critical: this is not a generic multivitamin with a "personalized" label printed on it. The ingredient selection, dosing levels, and bioavailable forms are all determined by your specific genetic results. Someone with a MTHFR C677T homozygous variant receives methylfolate, not folic acid. Someone with a slow COMT variant receives a different dopaminergic support strategy than someone with a fast-metabolizing variant.

But Neura doesn't stop at formulation. The platform includes a cognitive tracking protocol — validated assessments of working memory, processing speed, and mood — that run over time and feed back into your supplementation profile. This creates a closed loop that most health companies never attempt: test your genes, intervene with precision, measure your actual cognitive outcomes, and refine. It's the scientific method applied to your brain health.

Who Neura Is Built For

Neura sits at the intersection of several overlapping audiences, all united by a common frustration with the status quo.

Biohackers and quantified-self enthusiasts who have already done 23andMe or AncestryDNA but have never had anyone translate those raw SNP files into an actionable supplementation protocol. These users understand the science exists — they've just never had a product that applies it.

High-performance professionals — founders, surgeons, attorneys, traders — for whom cognitive edge is a professional asset. They're already spending $200–400/month on generic nootropic stacks. Neura offers a credentialed, science-backed alternative with actual accountability metrics.

Adults with family history of cognitive decline who carry APOE e4 status or other neuroinflammation risk variants and want to be proactive — not reactive — about long-term brain health. For this group, Neura isn't a wellness luxury; it's a preventive health strategy.

Functional medicine patients whose practitioners already order MTHFR panels and nutrigenomic workups but struggle to translate results into coherent supplement protocols. Neura can serve as the clinical-grade fulfillment layer for forward-thinking practitioners.

Why Neura Stands Apart

The "personalized supplement" space has attracted a lot of attention — and a lot of false claims. Companies like Care/of and Ritual have built large audiences by asking lifestyle questionnaires and calling the result "personalized." That's not personalization. That's segmentation.

Neura's differentiation is structural, not cosmetic. The genomic substrate means that two customers with identical lifestyles, ages, and health goals will receive meaningfully different formulations if their genetic variants differ — and those differences are scientifically defensible. The advisory board, which includes neurogenomics researchers from UCSF and veteran formulators with decades of evidence-based practice, provides the scientific credibility that casual wellness brands cannot replicate.

The Market Opportunity

Neura is entering at the intersection of three converging megatrends, each substantial on its own — and explosive in combination.

Consumer genomics has crossed the chasm. Over 28 million people have taken direct-to-consumer DNA tests in the United States alone, and a growing fraction of them are asking the same question: now that I know my variants, what do I actually do with this information? Neura answers that question — specifically for the brain.

Meanwhile, the cognitive wellness market is being turbocharged by an aging population increasingly focused on prevention, a post-pandemic generation acutely aware of brain fog and mental performance, and a professional class willing to invest seriously in cognitive optimization. The personalized nutrition sector specifically is projected to grow at a 12% compound annual rate through 2030, driven precisely by the shift from generic to genomic.

The regulatory and scientific infrastructure is also maturing. Nutrigenomic research has moved from fringe to mainstream, with peer-reviewed publications in journals like Nature Genetics and JAMA regularly validating the clinical relevance of variants Neura's panel covers. This is no longer speculative science — it's applied biology waiting for a company credible enough to deploy it at consumer scale.

Built with Artha — From Science to Company in Record Time

Neura is one of the companies built on Artha, an AI platform that takes a founding vision and constructs an entire company around it — brand, website, positioning, product architecture, and go-to-market strategy — from a single prompt. What would have taken months of agency work, founder sleepless nights, and six-figure spend in design and strategy was compressed into a fraction of the time.

The Artha-built foundation gave Neura's team the runway to focus on what matters most at the science layer: refining the genomic panel, building relationships with clinical advisors, and validating the cognitive tracking protocol. When the infrastructure of a company can be generated intelligently and rapidly, science-first founders can stay science-first.

"The supplement industry has ignored genomics for two decades. The science was always there. What was missing was a platform credible enough to bring it to consumers at scale."

What's Next for Neura

Neura's near-term roadmap is focused on building the data flywheel that will make the platform increasingly powerful over time. As more customers complete genomic profiles and longitudinal cognitive tracking, Neura builds a proprietary dataset linking specific variant combinations to real-world cognitive outcomes — an asset no generic supplement brand can replicate and no academic lab has the commercial incentive to build.

The practitioner channel represents a particularly compelling growth vector. Functional medicine and integrative health is a rapidly expanding clinical category, and practitioners currently lack a trusted, commercially available platform to translate their patients' nutrigenomic panels into actual supplement protocols. Neura can own that clinical workflow.

Longer term, the genomic-plus-tracking model Neura is building for brain health is a template that extends to any domain where genetic variants influence response to nutritional intervention — metabolic health, gut microbiome, cardiovascular risk, longevity. The brain is the beachhead. The platform is the prize.

Build Your Own Company with Artha

Neura went from a scientific insight — that the supplement industry was ignoring decades of nutrigenomic research — to a fully realized company with positioning, product architecture, and a brand identity ready to face the market. That's what Artha makes possible.

If you have a category insight, a founder hypothesis, or a market gap you've been thinking about, Artha can help you build the company around it — faster and more completely than any traditional approach. No agency retainers. No months lost to brand strategy. Just your idea, and a platform that knows how to build.

Start building on Artha →